Menu

Pharmaceutical giant Eli Lilly has significantly escalated its restrictions on access to 340B pricing in the contract pharmacy setting, the company announced June 19 on the drug industry vendor site 340B ESP.

Lilly Adds Significant New Restrictions on 340B Contract Pharmacy Access; Alleges Lack of Oversight by HRSA, Pharmacies and TPAs

June 21, 2024 Bella Czajkowski and Ted Slafsky, National Correspondent 340B Report Views

Pharmaceutical giant Eli Lilly has significantly escalated its restrictions on access to 340B pricing in the contract pharmacy setting, the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Bella Czajkowski and Ted Slafsky

Lilly Posts 340B Refund Notice for Insulin Product Humulin

PhRMA Asks Federal Judge to Block Enforcement of Maryland’s New 340B Contract Pharmacy Access Law